This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of QR402 - a first-in-class, oral nanomedicine that targets intestinal dendritic cells to restore immune tolerance and prevent the onset of type 1 diabetes. Awarded to Qrono, Inc., a for-profit biopharmaceutical company, the $306,500 grant will fund research to characterize and evaluate the tolerogenic effects of the AMPK pathway agonist PF-739 when delivered via enteric-coated nanoparticles specifically to intestinal dendritic cells. Successful completion of this project will establish proof-of-concept for this novel, dendritic cell-targeted preventative therapy for type 1 diabetes, and support further development of QR402 through preclinical studies and future clinical trials.
Generated 1/28/25, 10:15 AM